Morschhauser, Franck http://orcid.org/0000-0002-3714-9824
Dyer, Martin J. S.
Walter, Harriet S. http://orcid.org/0000-0003-2618-711X
Danilov, Alexey V.
Ysebaert, Loic
Hodson, Daniel James http://orcid.org/0000-0001-6225-2033
Fegan, Christopher
Rule, Simon A. http://orcid.org/0000-0001-8937-6351
Radford, John
Cartron, Guillaume
Bouabdallah, Krimo
Davies, Andrew John
Spurgeon, Stephen
Rajakumaraswamy, Nishanthan http://orcid.org/0000-0002-0226-0637
Li, Biao
Humeniuk, Rita
Huang, Xi
Bhargava, Pankaj
Jürgensmeier, Juliane M.
Salles, Gilles http://orcid.org/0000-0002-9541-8666
Funding for this research was provided by:
Gilead Sciences
Article History
Received: 17 July 2020
Revised: 17 November 2020
Accepted: 30 November 2020
First Online: 17 December 2020
Compliance with ethical standards
:
: FM serves on advisory boards for Roche, Celgene, Gilead Sciences, and Epizyme, has given expert testimony for Roche, and has received honoraria for scientific lectures for Janssen, Celgene and Roche; MJSD reports research funding from Roche, Gilead Sciences, Astex, BioInvent, and AstraZeneca; HSW has nothing to disclose; AVD reports research funding from Aptose Biosciences, Verastem Oncology, AstraZeneca, Gilead Sciences, Takeda Oncology, Genentech, Bayer Oncology, and Bristol Myers Squibb, and reports consultancy for Verastem Oncology, AstraZeneca, Gilead Sciences, Genentech, TG Therapeutics, Celgene, Curis, and Seattle Genetics; LY reports consultancy for AbbVie, AstraZeneca, Gilead, Janssen, and Roche; DJH reports research funding from Gilead Sciences; CF has nothing to disclose; SAR reports research funding from and consultancy for Janssen, Celgene, Roche, Sunesis, Celltrion, and AstraZeneca, and reports speakers bureau for Janssen; JR reports research funding from Takeda, reports consultancy for Takeda and Seattle Genetics, reports speakers bureau for Takeda, Bristol Myers Squibb, and ADC Therapeutics, and reports holding shares of GlaxoSmithKline and AstraZeneca; GC reports consultancy for Roche and Celgene; KB reports consultancy for Takeda and Gilead Sciences/Kite Pharma; AJD reports research funding from Roche, Celgene, Acerta/AstraZeneca, Gilead Sciences/Kite Pharma, Karyopharma, and ADC Therapeutics, and reports consultancy for Celgene, Roche, Takeda, Acerta/AstraZeneca, Karyopharm, MorphoSys AG, and Janssen; SS reports research funding from Velos BioPharma, Gilead Sciences, Janssen, Acerta Pharma, Bristol Myers Squibb, Genentech, and AstraZeneca, and reports consultancy for Janssen, Pharmacyclics, and Portola Pharmaceuticals; NR, BL, RH, XH, PB, and JMJ report employment with Gilead Sciences; and GS reports consultancy for AbbVie, Autolus Therapeutics, Celgene, Genmab, Gilead Sciences, Epizyme, Janssen, Karyopharm, Kite Pharma, Merck, MorphoSys, Novartis, Roche, Servier, and Takeda, and reports speakers bureau for AbbVie, Amgen, Celgene, Gilead Sciences, Janssen, Kite Pharma, MorphoSys, Novartis, Roche, Servier, and Takeda.